Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Update l'année dernière
Reference: NCT02824575

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.


Inclusion criteria

  • Breast Cancer,Breast Adenocarcinoma,Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Recurrent Breast Carcinoma,Stage IV Breast Cancer

Links